Tissue evacuated during joint replacement procedure as a source of mononuclear cells

Jakobsons Eriks1,2, Erglis Kristaps1, Patetko Liene1

  • 1Cell Transplantation Centre, Pauls Stradins Clinical University Hospital, Riga, Latvia.

Insights

Excess tissue from joint replacement surgery is a significant source of mononuclear cells. Standard bone marrow cell extraction methods can be adapted for this valuable surgical byproduct, offering a new resource for cell-based therapies.

Area of Science:

  • Regenerative Medicine
  • Cell Biology
  • Orthopedic Surgery

Background:

  • Bone marrow mononuclear cells are utilized in clinical trials for cardiac diseases and other conditions.
  • Current clinical studies involve patients with cardiac diseases, coronary disease, type 2 diabetes, and osteoarthritis.
  • Excess tissue from joint replacement procedures is typically discarded.

Purpose of the Study:

  • To determine if tissue removed during joint replacement surgery is a viable source of mononuclear cells.
  • To compare the yield of mononuclear cells from joint replacement tissue versus bone marrow.

Main Methods:

  • Mononuclear cells were isolated from both joint replacement tissue and bone marrow using Ficoll density gradient centrifugation.
  • Flow cytometry was employed to quantify mononuclear cells and CD34+ populations.
  • Cell viability was assessed, and tissue processing yields were compared between the two sources.

Main Results:

  • Processing joint replacement tissue yielded an average of 76.67 × 10^6 mononuclear cells (MNCs) and 1.33 × 10^6 CD34+ cells per sample.
  • Bone marrow processing yielded an average of 28.64 × 10^6 MNCs and 0.77 × 10^6 CD34+ cells per sample.
  • Joint replacement tissue provided a significantly higher yield of MNCs and CD34+ cells compared to bone marrow.

Conclusions:

  • Tissue removed during joint replacement surgery is a significant source of mononuclear cells.
  • Established methods for bone marrow-derived mononuclear cell extraction are applicable to excess joint replacement tissue.
  • This finding presents an opportunity to utilize surgical byproducts for cell-based therapies.
Abstract